ADVERTISEMENT Individual Results May Vary Jessica’s story: Seeing is believing

Jessica Salazar of Edinburg, TX was a teenager when she was first diagnosed with diabetes. At age 29, when she started having vision problems, Jessica was diagnosed with diabetic macular edema (DME), the disease that cost her mother her eyesight.

“It was bad,” she said of her vision. “I had to quit my teaching job because I couldn’t read my lesson plans. I couldn’t drive anymore. When students at a distance called my name, I had no idea who they were.”

By the time she first saw her retinal specialist, Victor Gonzalez, MD in McAllen, TX, Jessica was legally blind in one eye, visually impaired in the other. He prescribed a standard treatment of regular injections – every six to eight weeks – in each eye to reduce edema.

The treatments helped, but the frequent visits presented another challenge. “It was like going to the hospital. You knew you were going to get poked. They gave me anesthesia before I got the injections. I’d protect my eyes as much as possible, tried to stay out of the sun. But usually when I got home, I’d just lie down and go to sleep.”

About a year ago Dr. Gonzalez offered her an implant for both of her eyes that would release a corticosteroid over a three year period with a single injection, ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg. He advised her that her vision should improve, but she may develop a cataract and may require drops to control eye pressure, as with all corticosteroids. While

Indication: ILUVIEN® (fluocinolone acetonide intravitreal implant)

0.19mg is an implant injected into the eye (vitreous) and used for the treatment of diabetic macular edema (DME) in patients who have been treated with corticosteroids before and did not have a significant increase in eye pressure.

Important Safety Information

• Do not use ILUVIEN if you have or think you might have an infection in or around the eye, or if you are allergic to any ingredients in ILUVIEN.

• Injections can be associated with a serious eye infection (endoph- thalmitis), eye inflammation, increased eye pressure, glaucoma, and retinal detachments. Your eye doctor should monitor you regularly after the injection.

• Use of corticosteroids, including ILUVIEN, may produce cataracts, increased eye pressure, glaucoma, and may increase secondary eye infections due to bacteria, fungi, or viruses. Let your doctor

the implant meant reduced treatment frequency for Ms. Salazar, the benefit went beyond convenience.

With the help of corrective lenses, her eyesight is now 20/40 in one eye, 20/50 in the other. She is so grateful to Dr. Gonzalez for telling her about ILUVIEN.

“I can actually do more things, like reading and driving. And when people come up to me from a distance, I know who they are!”

She still visits her doctor every month, so he can check her progress.

ILUVIEN has not been studied for its effect on driving, general reading or writing. Talk to your doctor to see if ILUVIEN may be an option for you.

know if you have a history of herpes viral infections of the eye.

• After an injection with ILUVIEN, a cataract may occur. If this occurs, your vision will decrease and you will need an operation to remove the cataract and restore your vision. You may develop increased eye pressure with ILUVIEN that will need to be managed with eye drops, and rarely, with surgery.

• In patients with a torn or absent posterior lens capsule, there is a risk of the implant migrating from the back of the eye to the front of the eye.

• The most common side effects reported in patients with diabetic macular edema who were treated with ILUVIEN include cataracts and increased eye pressure.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

Please see Patient Information on following page.

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68